Johnson & Johnson $JNJ Shares Bought by Cerity Partners LLC

Cerity Partners LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,811,564 shares of the company’s stock after purchasing an additional 39,452 shares during the quarter. Cerity Partners LLC owned 0.08% of Johnson & Johnson worth $276,797,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in JNJ. Rockport Wealth LLC purchased a new stake in Johnson & Johnson during the second quarter worth $475,000. Cary Street Partners Investment Advisory LLC raised its position in shares of Johnson & Johnson by 5.4% in the second quarter. Cary Street Partners Investment Advisory LLC now owns 3,418 shares of the company’s stock worth $522,000 after acquiring an additional 174 shares during the period. PGIM Custom Harvest LLC boosted its stake in shares of Johnson & Johnson by 7.1% during the 2nd quarter. PGIM Custom Harvest LLC now owns 1,886 shares of the company’s stock worth $288,000 after acquiring an additional 125 shares in the last quarter. Stenger Family Office LLC acquired a new stake in shares of Johnson & Johnson during the 2nd quarter valued at about $2,625,000. Finally, Victory Financial Group LLC increased its stake in shares of Johnson & Johnson by 5.6% in the 2nd quarter. Victory Financial Group LLC now owns 4,385 shares of the company’s stock valued at $670,000 after purchasing an additional 231 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

JNJ has been the topic of several research analyst reports. Sanford C. Bernstein raised their price objective on Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a report on Monday, October 6th. Royal Bank Of Canada reissued an “outperform” rating and issued a $209.00 price target on shares of Johnson & Johnson in a research note on Friday, October 10th. Guggenheim upped their price objective on shares of Johnson & Johnson from $206.00 to $227.00 and gave the stock a “buy” rating in a research report on Friday. Scotiabank began coverage on shares of Johnson & Johnson in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $230.00 target price on the stock. Finally, Bank of America upped their price target on shares of Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 15th. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $203.15.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $201.92 on Friday. The firm has a 50-day simple moving average of $194.05 and a 200-day simple moving average of $175.40. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $486.48 billion, a price-to-earnings ratio of 19.49, a price-to-earnings-growth ratio of 2.25 and a beta of 0.36. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $207.81.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The company had revenue of $24.02 billion during the quarter. On average, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.6%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.